In adults, prophylactic botulinum toxin A reduces frequency of chronic migraine headaches and chronic daily headaches but increases adverse events. 
Conclusion
In adults, prophylactic botulinum toxin A reduces frequency of chronic migraine headaches and chronic daily headaches but increases adverse events. 
*

Commentary
Jackson and colleagues conclude that botulinum toxin may help chronic migraine and chronic daily headaches. They suggest that the latter group benefited because patients with chronic migraines were included; we address the claim of benefit for chronic migraine.
Jackson and colleagues note that trials included in their review were mostly small, short, and industry-sponsored. They acknowledge that botulinum toxin may be less beneficial than other prophylactic medications. However, we believe that their conclusions are still optimistic. We closely examined the 2 PREEMPT trials, which contributed 92% of patients (1384/1508) to the meta-analysis of chronic migraine. First, we strongly agree with concerns expressed by Olesen and Tfelt-Hansen about the inability to blind patients owing to the paralytic effects of the drug (1) . Second, about two thirds of patients had medication overuse (1) . In 2010, the PRE-EMPT Chronic Migraine Study Group promised a separate analysis of this subgroup; however, we have been unable to find a report of such an analysis. Finally, the PREEMPT 2 trial changed its primary outcome after the trial started based on the results of the PREEMPT 1 trial.
Although the meta-analysis suggests benefits with botulinum, it does not address whether these benefits are clinically important. When a patient has ≥ 15 headaches per month, having 2 to 3 fewer seems less than robust, especially at a cost of $1000 to $2000 per treatment (2) . In addition, long-term safety is uncertain. Botulinum toxin is probably safe in long-term treatment of dystonias (3); however, because it incompletely prevents migraines, patients may request more frequent dosing, which may lead to toxicity.
We remain skeptical about botulinum toxin A for preventing chronic migraine. 
Review scope
Included studies compared botulinum toxin A, alone or combined with other prophylactic or analgesic treatments, with placebo or other treatments in adults who had headaches; were ≥ 4 weeks in duration; and reported headache frequency or severity. Exclusion criteria were headaches associated with other disorders (e.g., cervical dystonia) or secondary headaches (e.g., postlumbar puncture headaches). Outcomes were patient-reported headache frequency or severity, indices that included patient-reported headache frequency and severity, and adverse events.
Review methods
MEDLINE, EMBASE/Excerpta Medica, Cochrane Library, and reference lists were searched to March 2012 for randomized controlled trials (RCTs). 31 RCTs met inclusion criteria: 27 used placebo controls (n = 5423, mean age 42 y, 76% women) and 4 used active controls (n = 210, mean age range 30 to 42 y, 89% women), including topiramate, amitriptyline, methylprednisolone, and valproate. 10 placebo-controlled trials evaluated treatment for episodic migraine headaches (< 15 headaches/mo), 8 for chronic tension-type headaches (≥ 15 headaches/mo), 5 for chronic migraine headaches, 3 for chronic daily migraine or tension-type headaches, and 1 for a mixed population; 2 active-controlled trials evaluated treatment for chronic migraine headaches and 2 for a mixed population. 17 placebo-controlled RCTs and 1 active-controlled RCT scored ≥ 6 out of 8 on the Jadad scale for methodological quality.
Main results
Botulinum toxin A reduced frequency of chronic migraine and chronic daily headaches more than placebo; groups did not differ for reducing frequency of episodic migraine or chronic tensiontype headaches (Table) . In single RCTs, botulinum toxin A reduced the severity of chronic tension-type headaches more than methylprednisolone; botulinum toxin A did not differ from topiramate, valproate, or amitriptyline for reducing headache frequency. Botulinum toxin A increased adverse events more than placebo (25 RCTs; 57% vs 46%; relative risk increase 25%, 95% CI 14 to 36; number needed to harm 9, CI 7 to 16*). 
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